LONDON May 7 AstraZeneca, fighting a
$106 billion bid approach from Pfizer, is talking to
other companies as it seeks a partnering deal for its
experimental Alzheimer's drug.
Briggs Morrison, global head of medicines development, said
AstraZeneca was talking to companies with more experience of
Alzheimer's about a deal to share development of its so-called
BACE inhibitor drug, which is set to enter late-stage Phase III
A deal to share Phase III costs and share eventual profits
was probably the easiest approach, he told reporters on
Wednesday, but AstraZeneca could also out-license the product
and take a royalty on any eventual sales.
AstraZeneca believes its BACE inhibitor could potentially
sell as much as $5 billion a year, but it gives it only a 9
percent chance of success on a risk adjusted basis given the
high failure rate in the disease sector.
The British company on Tuesday set out its defence against
the Pfizer takeover, touting its strong long-term growth
potential as an independent company.
(Reporting by Ben Hirschler, editing by Kate Holton)